ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the ticker ADRX. The offering comes with backing from AbbVie Inc. (NYSE:ABBV) has agreed to invest up to $100 million through a concurrent private placement, which ADARx said would give AbbVie a roughly 4.9% stake following the IPO.
DON’T MISS: Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
That relationship between the two companies isn’t entirely new, as AbbVie paid ADARx $335 million in May 2025 as part of a research collaboration. Now, prospective shareholders have to decide whether ADARx’s pipeline and pharma backing justify a valuation approaching $1.74 billion in an IPO market that remains selective.
Bull Case
AbbVie’s involvement is one of the clearest positives surrounding the offering. IPOX Research Associate Lukas Muehlbauer described the planned investment as external validation of ADARx’s technology, and AbbVie has agreed to invest as much as $100 million alongside the IPO after previously paying ADARx $335 million for a research collaboration in May 2025.
ADARx also enters the public market with multiple programs already progressing through development. Three of its experimental drugs are in clinical testing, while another two are in advanced preclinical development. Its pipeline targets diseases involving the immune, kidney, cardiovascular, and neurological systems. Most importantly, ADARx isn’t entering the market with only early-stage programs. Its most advanced candidate, onvuzosiran, is already in late-stage testing for hereditary angioedema, a rare genetic disorder that causes sudden swelling attacks.
READ ALSO: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
That could be particularly relevant in the current IPO environment. Muehlbauer said the reopening of the biotech IPO market remains selective, favoring companies with later-stage assets, upcoming catalysts, and exposure to areas including obesity and oncology. There are also signs that biotech IPO activity has improved from a year ago. Reuters reported that biotech offerings have broadly rebounded from year-ago levels. Electra Therapeutics recently raised $350 million in an upsized IPO, while Retension Pharmaceuticals and TRex Bio have also filed for listings.
Bear Case
The $1.74 billion valuation still asks investors to place substantial value on a company whose drugs remain experimental. ADARx has three programs in clinical testing and two in advanced preclinical development. Even onvuzosiran, the company’s most advanced candidate, remains in late-stage testing.
When assessing the IPO valuation, clinical results for onvuzosiran, ADARx’s revenue, losses, cash burn, or expected timeline to commercialization are essential to determine whether the proposed valuation is cheap or expensive. The broader IPO backdrop isn’t entirely supportive either. Reuters noted that a sharp increase in Treasury yields and higher interest rates has pushed some prospective issuers to the sidelines. And although biotech offerings have recovered from year-ago levels, Muehlbauer characterized the reopening as selective rather than broad.
DON’T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
AbbVie’s investment should also be kept in perspective. The commitment of up to $100 million is meaningful enough for Muehlbauer to characterize it as external validation, but it does not remove the clinical-development risks inherent in ADARx’s pipeline. AbbVie’s planned stake would amount to roughly 4.9% following the IPO.
Conclusion
ADARx is coming to market with several attributes that could help it stand out in a selective biotech IPO environment, including a late-stage lead candidate, several additional development programs, and financial backing from AbbVie Inc.. But the proposed valuation of up to $1.74 billion ultimately rests on experimental medicines whose commercial outcomes remain undetermined.
For prospective ADARx investors, that leaves a relatively clear divide. AbbVie’s involvement and onvuzosiran’s late-stage status strengthen the story behind the IPO, while the absence of an approved product and the inherently uncertain path from clinical development to commercialization remain central risks as ADARx seeks as much as $371.9 million from the offering.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
